Trial Profile
A Randomized, Open-label, Multiple-centre Study of Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced NSCLC With EGFR Mutation Positive
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Nov 2017 Status changed from recruiting to discontinued.
- 20 Jan 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 28 Nov 2014 New trial record